natgillin/translations-raw huggingface dataset:
reacting the compound according to formula (6), or salt thereof, with an organometallic reagent derived from 4-methyl biphenyl to obtain a compound according to formula (22), or salt thereof, 
reakcija spoja prema formuli (6) ili njegove soli, s organometalnim reagensom izvedenim iz 4-metil-bifenila, kako bi se dobio spoj u skladu sa sljedećom formulom (22) ili njegova sol:
A process for preparing a compound according to formula (22), or salt thereof, wherein R1 is hydrogen or a nitrogen protecting group, said process comprising reacting the compound according to formula (6), or salt thereof, wherein R1 is hydrogen or a nitrogen protecting group, with an organometallic reagent derived from 4-methyl biphenyl to obtain the compound according to formula (22), or salt thereof. 
[image] gdje R1 je vodikova ili dušikova zaštitna skupina, naznačen time, da navedeni postupak obuhvaća reakciju spoja u skladu sa sljedećom formulom (6) ili njegove soli: [image] gdje R1 je vodikova ili dušikova zaštitna skupina, s organometalnim reagensom izvedenim iz 4-metil-bifenila, kako bi se dobio spoj u skladu s formulom (22) ili njegova sol.
A process for preparing a compound according to formula (21), or salt thereof, wherein R1 is hydrogen or a nitrogen protecting group, said process comprising dehydrating a compound according to formula (22), or salt thereof, wherein R1 is hydrogen or a nitrogen protecting group, to obtain the compound according to formula (21), or salt thereof. 
[image] gdje R1 je vodikova ili dušikova zaštitna skupina, naznačen time, da navedeni postupak obuhvaća dehidrataciju spoja u skladu sa sljedećom formulom (22) ili njegove soli: [image] gdje R1 je vodikova ili dušikova zaštitna skupina, kako bi se dobio spoj u skladu s formulom (21) ili njegova sol.
methylating the compound according to formula (1), or salt thereof, to obtain a compound according to formula (2), or salt thereof, 
metilacija spoja prema formuli (1) ili njegove soli, kako bi se dobio spoj u skladu sa sljedećom formulom (2) ili njegova sol:
A compound according to claim 60 in crystalline form. 
Spoj prema zahtjevu 60, naznačen time, daje u kristalnom obliku.
a mouthpiece or nosepiece (60); 
nastavak za usta ili nos (60);
An inhalator according to any one of the preceding claims, wherein the two parts (71, 72) of the shell (c) are adapted to fit manually releasably to each other in the closed condition of the shell (c). 
Inhalator prema bilo kojem od prethodnih zahtjeva, gdje su dva dijela (71, 72) kućišta (c) podešena da se ručno na odvojivi način međusobno namjeste u zatvorenom položaju kućišta (c).
The topical formulation of claim 1, wherein the blended HLB of the first hydrophilic and second hydrophobic surfactants is 13.6. 
Topikalna formulacija prema patentnom zahtjevu 1, naznačena time što, miješana HLB prvog hidrofilnog i drugog hidrofobnog surfaktanta je 13.6.
A stable topical formulation comprising: 
Stabilna topikalna formulacija koja sadrži:
The compound, tautomer, stereoisomer, mixture of stereoisomers, or pharmaceutically acceptable salt, solvate or hydrate of claim 1, or a pharmaceutically acceptable salt thereof, wherein the moiety has one of the following structures: or 
Spoj, tautomer, stereoizomer, smjesa stereoizomera, ili farmaceutski prihvatljiva sol, solvat ili hidrat prema zahtjevu 1, ili njihova farmaceutski prihvatljiva sol, naznačen time da skupina [image] ima jednu od slijedećih struktura: [image] ili [image]
An apparatus according to claim 1, wherein the apparatus comprises a floating platform (2) connected to the vessel (1) for supporting the vessel and keeping the vessel partially above surface level of the body of water, which floating platform advantageously provides space for spectators. 
Uređaj prema zahtjevu 1, pri čemu uređaj sadrži plutajuću platformu (2) koja je spojena na spremnik (1) za držanje spremnika i održavanje spremnika djelomično iznad razine vode,koja plutajuća platforma pruža pogodan prostor za gledatelje.
An apparatus according to any of claims 1-6, wherein the vessel (1, 5, 14, 17, 21) is equipped with an air-lock-type means for entering the vessel from the portion of the vessel located above surface level of the body of water. 
Uređaj prema bilo kojem od zahtjeva 1-6, pri čemu je spremnik (1, 5, 14, 17, 21) opremljen sredstvom tipa zračnog zaključavanja za ulazak u spremnik iz dijela spremnika smještenog iznad razine površine vode.
An apparatus according to any of claim 1-8, wherein the vessel (14) is equipped with a surface or platform (13) located inside the vessel and at the lower portion of the vessel, and at a distance from the closest surfaces of the vessel. 
Uređaj prema bilo kojem od zahtjeva 1-8, pri čemu je spremnik (14) opremljen površinom ili platformom (13) koja se nalazi unutar spremnika, i na donjem dijelu spremnika te na udaljenosti od najbližih površina spremnika.
Y is selected from the group consisting of C-R2 and a nitrogen atom; 
– Y se bira iz skupine koju čine C-R2 i atom dušika;
and R9 are independently selected from the group consisting of hydrogen atom, cycloalkyl and alkyl of three or four carbon atoms, linear or branched and optionally substituted by halogen or an aryl or heterocyclic group; or R8 and R9 form, together with the nitrogen atom to which they are attached a saturated five- or six-membered ring which optionally comprises a further heteroatom selected from the group consisting of oxygen and nitrogen optionally substituted by a (C1-C8) alkyl group; 
i R9 se neovisno bira iz skupine koju čine atom vodika, cikloalkil i alkil s tri ili četiri atoma ugljika, nerazgranat ili razgranat i može biti supstituiran s halogenom ili arilnom ili heterocikličkom skupinom; ili R8 i R9, zajedno s atomom dušika na kojeg su vezani, tvore zasićeni pet- ili šesteročlani prsten, koji može sadržavati dodatni heteroatom, kojeg se bira iz skupine koju čine kisik i dušik, može biti supstituiran s (C1-C8) alkilnom skupinom;
is selected from the group consisting of hydrogen, halogen, cycloalkyl group and a (C1-C8) alkyl group, linear or branched optionally substituted by halogen atoms; 
– R3 se bira iz skupine koju čine vodik, halogen, cikloalkilna skupina i (C1-C8) alkilna skupina, nerazgranata ili razgranata, koja može biti supstituirana s atomima halogena;
X is selected from the group consisting of halogen atom and cyano group; 
– X se bira iz skupine koju čine atom halogena i cijano skupina;
R4, R5 and R6 are independently selected from the group consisting of: 
– R4, R5 i R6 se neovisno bira iz skupine koju čine:
an alkyl, cycloalkyl or cycloalkylalkyl group having a maximum of five carbon atoms, linear or branched, optionally substituted by one or more halogen atoms, methoxy groups, or heteroaryl group, said heteroaryl group being optionally substituted with halogen atoms or (C1-C8) alkyl groups; 
alkilna, cikloalkilna ili cikloalkilalkilna skupina s najviše pet atoma ugljika, nerazgranata ili razgranata i može biti supstituirana s jednim ili više atoma halogena, metoksi skupina ili heteroarilnih skupina, gdje navedena heteroarilna skupina može biti supstituirana s atomima halogena ili (C1-C8) alkilnim skupinama;
or R5 and R6 can form, together with the nitrogen atom to which they are attached a pyrazole or triazole ring optionally substituted by halogen atoms and pharmaceutically acceptable salts thereof. 
ili R5 i R6 mogu, zajedno s atomom dušika na kojeg su vezani, tvoriti pirazolni ili triazolni prsten, koji može biti supstituiran s atomima halogena i njegove farmaceutski prihvatljive soli.
A compound according to claim 3 in which R6 is selected from the group consisting in alkyl, cycloalkylalkyl and alkylcycloalkyl optionally substituted with a methoxy group or a heteroaryl, which in turn can be optionally substituted by a (C1-C8) alkyl group. 
Spoj u skladu s patentnim zahtjevom 3, naznačen time što se R6 bira iz skupine koju čine alkil, cikloalkilalkil i alkilcikloalkil, koji može biti supstituiran s metoksi skupinom ili heteroarilom, koji pak može biti supstituiran s (C1-C8) alkilnom skupinom.
A compound according to claim 4 in which R6 is selected from the group consisting in ethyl, propyl, and cyclopropylmethyl, all of them being optionally substituted by a methoxy group or a five-membered heteroaryl group, which in turn is optionally substituted by one or more methyl groups. 
Spoj u skladu s patentnim zahtjevom 4, naznačen time što se R6 bira iz skupine koju čine etil, propil, i ciklopropilmetil, od kojih sve mogu biti supstituirane s metoksi skupinom ili peteročlanom heteroarilnom skupinom, koja pak može biti supstituirana s jednom ili više metilnih skupina.
A compound according to claim 3 in which R6 is selected from the group consisting groups allyl, propargyl and tetrahydropyranyl all of them being optionally substituted with an alkyl group, linear or branched, having a maximum of three carbon atoms. 
Spoj u skladu s patentnim zahtjevom 3, naznačen time što se R6 bira iz skupine koja se sastoji od skupine alil, propargil i tetrahidropiranil od kojih sve mogu biti supstituirane s alkilnom skupinom, nerazgranatom ili razgranatom, s najviše tri atoma ugljika.
A compound according to claim 8 in which R6 is selected from the group consisting of alkyl, cycloalkylalkyl and alkylcycloalkyl groups, all of them being optionally substituted with a methoxy group or with a heteroaryl group which, in turn, is optionally substituted by a (C1-C8) alkyl group. 
Spoj u skladu s patentnim zahtjevom 8, naznačen time što se R6 bira iz skupine koju čine alkilna, cikloalkilalkilna i alkilcikloalkilna skupina, od kojih sve mogu biti supstituirane s metoksi skupinom ili s heteroarilnom skupinom, koja pak može biti supstituirana s (C1-C8) alkilnom skupinom.
A compound according to claim 8 in which R6 is selected from the group consisting in ethyl, propyl, and cyclopropylmethyl, optionally substituted by a methoxy group or by a five-membered heteroaryl group optionally substituted by one or more methyl groups. 
Spoj u skladu s patentnim zahtjevom 8, naznačen time što se R6 bira iz skupine koju čine etil, propil, i ciklopropilmetil, koji može biti supstituiran s metoksi skupinom ili s peteročlanom heteroarilnom skupinom, koja može biti supstituirana s jednom ili više metilnih skupina.
A compound according to claim 8 in which R6 is selected from the group consisting of allyl, propargyl and tetrahydropyranyl groups optionally substituted by halogen atoms. 
Spoj u skladu s patentnim zahtjevom 8, naznačen time što se R6 bira iz skupine koju čine alilnu, propargilnu i tetrahidropiranilnu skupinu, koje mogu biti supstituirane s atomima halogena.
A compound according to claim 12 wherein R2 and R3 form, together with the atoms of carbon to which they are attached, a phenyl or pyridine rings optionally substituted by halogen atoms. 
Spoj u skladu s patentnim zahtjevom 12, naznačen time što R2 i R3, zajedno s atomima ugljika na kojeg su vezani, tvore fenilni ili piridinski prsten, koji mogu biti supstituirani s atomima halogena.
A compound according to claim 13 in which R6 is selected from the group consisting of alkyl, cycloalkylalkyl and alkylcycloalkyl optionally substituted with a methoxy group or a heteroaryl group which, in turn, is optionally substituted by a (C1-C8) alkyl group. 
Spoj u skladu s patentnim zahtjevom 13, naznačen time što se R6 bira iz skupine koju čine alkil, cikloalkilalkil i alkilcikloalkil, koji može biti supstituiran s metoksi skupinom ili heteroarilnom skupinom, koja pak može biti supstituirana s (C1-C8) alkilnom skupinom.
A compound according to claim 14 in which R6 is selected from the group consisting of ethyl, propyl and cyclopropylmethyl, optionally substituted by a methoxy group or by a five-membered heteroaryl group optionally substituted by one or more methyl groups. 
Spoj u skladu s patentnim zahtjevom 14, naznačen time što se R6 bira iz skupine koju čine etil, propil i ciklopropilmetil, može biti supstituiran s metoksi skupinom ili s peteročlanom heteroarilnom skupinom, koja može biti supstituirana s jednom ili više metilnih skupina.
A compound according to claim 13 in which R6 is selected from the group consisting of optionally substituted allyl, propargyl, and tetrahydropyranyl. 
Spoj u skladu s patentnim zahtjevom 13, naznačen time što se R6 bira iz skupine koju čine izborno supstituirani alil, propargil i tetrahidropiranil.
A compound according to claim 2 in which R1 and R5 represent a hydrogen atom, X represents a bromine atom, Y represents a CR2 moiety, R2 and R3 form, together with the carbon atoms to which are attached, a phenyl or pyridine ring and R6 is selected from the group consisting of ethyl, propyl and cyclopropylmethyl optionally substituted by a thiazole ring, which is optionally substituted by one or more methyl groups. 
Spoj u skladu s patentnim zahtjevom 2, naznačen time što R1 i R5 predstavljaju atom vodika, X predstavlja atom broma, Y predstavlja ostatak CR2, R2 i R3, zajedno s atomima ugljika na koje su vezani, tvore fenilni ili piridinski prsten, a R6 se bira iz skupine koju čine etil, propil i ciklopropilmetil, koji može biti supstituiran s tiazolnim prstenom, koji može biti supstituiran s jednom ili više metilnih skupina.
A compound according to claim 2 in which R1, R3 and R5 represent a hydrogen atom, X represents a bromine atom, Y represents a nitrogen atom, and R6 is selected from the group consisting of ethyl, propyl, propargyl and cyclopropylmethyl optionally substituted by a thiazole ring, which in turn is optionally substituted by one or more methyl groups. 
Spoj u skladu s patentnim zahtjevom 2, naznačen time što R1, R3 i R5 predstavljaju atom vodika, X predstavlja atom broma, Y predstavlja atom dušika, a R6 se bira iz skupine koju čine etil, propil, propargil i ciklopropilmetil, koji može biti supstituiran s tiazolnim prstenom, koji pak može biti supstituiran s jednom ili više metilnih skupina.
A compound according to claim 1, which is selected from the group consisting of: 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što se bira iz skupine koju čine:
A compound according to any of claims 1 to 19 for use in the treatment of a disease or pathological condition susceptible of improvement by inhibition of Phosphodiesterase 10,, wherein the disease or pathological condition susceptible of improvement by inhibition of Phosphodiesterase 10 is selected from the group consisting of diseases and pathological conditions of the central nervous system such as schizophrenia, Huntington's disease, Parkinson's disease, Alzheimer's disease, and depression, and respiratory disorders such as pulmonary hypertension, asthma and COPD. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 19, naznačen time što je namijenjen upotrebi u liječenju bolesti ili patološkom stanju podložnom poboljšanju inhibiranju fosfodiesteraze 10, gdje se bolest ili patološko stanje podložno poboljšanju inhibiranju fosfodiesteraze 10 bira iz skupine koju čine bolesti i patološka stanja središnjeg živčanog sustava, poput shizofrenije, Huntingtonove bolesti, Parkinsonove bolesti, Alzheimerove bolesti i depresije, te respiratorni poremećaji, poput plućne hipertenzije, astme i COPD-a.
Method according to any one of the previous claims, characterised in that the binding back (7) is a V-shaped or U-shaped binding back and that the distance (A) essentially corresponds to the depth of the binding back (7). 
Postupak sukladno bilo kojem od prethodnih zahtjeva, naznačen time što je uvez (7) oblika slova V ili U i da udaljenost (A) u osnovi odgovara dubini uveza (7).
Method according to any one of the previous claims, characterised in that the distance (A) is somewhat greater than the depth of the binding back (7) . 
Postupak sukladno bilo kojem od prethodnih zahtjeva, naznačen time što je udaljenost (A) nešto veća od dubine uveza (7).
Method according to any one of the previous claims, characterised in that the bundle (5) is stapled beforehand. 
Postupak sukladno bilo kojem od prethodnih zahtjeva, naznačen time što je snop (5) prethodno spojen.
Device according to claim 21 or 22, characterised in that the rigid plates (18) are made of steel and have a thickness of approximately 0.3 millimetres. 
Uređaj sukladno zahtjevu 21 ili 22, naznačen time što su čvrste ploče (18) načinjene od čelika debljine otprilike 0.3 milimetra.
2-Ethoxy-N-(3-hydroxy-4,4-dimethyl-pentyl)-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide, optionally in the form of a single stereoisomer or a mixture of stereoisomers, in the form of the free compound and/or a physiologically acceptable salt thereof. 
amid 2-etoksi-N-(3-hidroksi-4,4-dimetil-pentil)-4-metil-6-morfolin-4-il-piridin-3-karboksilne kiseline, proizvoljno u obliku jednog stereoizomera ili smjese stereoizomera, u obliku slobodnog spoja i/ili njegove fiziološki prihvatljive soli.
A pharmaceutical composition comprising at least one compound according to any of the preceding claims, optionally in the form of a single stereoisomer or a mixture of stereoisomers, in the form of the free compound and/or a physiologically acceptable salt thereof, and optionally at least one pharmaceutically acceptable auxiliary. 
Farmaceutski pripravak naznačen time da sadrži barem jedan spoj prema bilo kojem od prethodnih zahtjeva, proizvoljno u obliku jednog stereoizomera ili smjese stereoizomera, u obliku slobodnog spoja i/ili njegove fiziološki prihvatljive soli, te proizvoljno barem jednu farmaceutski prihvatljivu pomoćnu tvar.
The composition according to claim 13 for use in the treatment and/or prophylaxis of disorders and/or diseases selected from the group consisting of pain, preferably pain selected from the group consisting of acute pain, chronic pain, neuropathic pain, muscular pain, visceral pain and inflammatory pain, epilepsy, urinary incontinence, anxiety, dependency, mania, bipolar disorders, migraine, cognitive diseases and dystonia-associated dyskinesias. 
Pripravak prema zahtjevu 13 naznačen time da je za uporabu u liječenju i/ili sprječavanju poremećaja i/ili bolesti koje se biraju iz skupine koju čine bol, poželjno bol koja se bira iz skupine koju čine akutna bol, kronična bol, neuropatska bol, bol u mišićima, visceralna bol i upalna bol, epilepsija, urinarna inkontinencija, anksioznost, ovisnost, manija, bipolarni poremećaj, migrena, kognitivni poremećaji i diskinezije povezane s distonijom.
and wherein R1 and R2 taken together or Ra and Rb taken together along with the carbon to which they are attached are cyclopropyl; 
i pri čemu R1 i R2 uzeti zajedno ili Ra i Rb uzeti zajedno i s ugljikom na koji oni vezani su ciklopropil;
A pharmaceutical composition comprising a compound of formula IIB: or a pharmaceutically acceptable salt, solvate, stereoisomer and/or ester thereof, wherein: 
Farmaceutski sastav koji sadrži spoj formule IIB: [image] ili njegovu farmaceutski prihvatljivu sol, solvat, stereoizomer i/ili ester, gdje:
The pharmaceutical composition of claim 1 comprising a compound of formula IIB, or a pharmaceutically acceptable salt, solvate, stereoisomer and/or ester thereof, wherein R13 is -(CH2)0-3CR17R18NR20R21, -(CH2)0-3CR17R18NR17C(O)NR20R21 or -(CH2)1-3-R23. 
Farmaceutski sastav prema zahtjevu 1 koji sadrži spoj formule IIB, ili njegovu farmaceutski prihvatljivu sol, solvat, stereoizomer i/ili ester, gdje R13 je -(CH2)0-3CR17R18NR20R21, -(CH2)0-3CR17R18NR17C(O)NR20R21 ili -(CH2)1-3-R23.
The pharmaceutical composition of claim 2 comprising a compound of formula IIB, or a pharmaceutically acceptable salt, solvate, stereoisomer and/or ester thereof, wherein R13 is -(CH2)0-3CR17R18NR20R21 or -(CH2)0-3CR17R18NR17C(O)-NR20R21. 
Farmaceutski sastav prema patentnom zahtjevu 2, koji sadrži spoj formule IIB, ili njegovu farmaceutski prihvatljivu sol, solvat, stereoizomer i/ili ester, naznačeno time što R13 je -(CH2)0-3CR17R18NR20R21 ili -(CH2)0-3CR17R18NR17C(O)-NR20R21.
The pharmaceutical composition of claim 1 wherein the compound of formula IIB is a compound of formula IIC: or a pharmaceutically acceptable salt, solvate, stereoisomer and/or ester thereof, wherein: 
Farmaceutski sastav prema zahtjevu 1, gdje spoj formule IIB spoj formule IIC: [image] ili njegova farmaceutski prihvatljiva sol, solvat, stereoizomer i/ili ester, gdje:
mixing the product obtained in step b) with a mixture obtained by methacrylic resin and poly(dimethylsiloxane)-terminated vinyl functionalized with mercaptosilane, and 
miješanje produkta dobivenog u stupnju b) sa smjesom dobivenom od metakrilne smole i funkcionaliziranog poli(dimetilsiloksana) s vinilom na kraju,
mixing the product obtained in step b) with a mixture obtained by 5-60% by weight of a methacrylic resin and 2-5% by weight of poly(dimethylsiloxane)-terminated vinyl functionalized with mercaptosilane, and 
miješanje produkta dobivenog u stupnju b) sa smjesom dobivenom od 5-60 tež.% metakrilne smole i 2-5 tež.% funkcionaliziranog poli(dimetilsiloksana) s vinilom na kraju.
The composition of claim 2, comprising 40-60% (w/w) carbohydrates obtainable from carob, and 40-60% (w/w) carbohydrates obtainable from apple, wherein the percentages are based on the dry matter. 
Pripravak u skladu s patentnim zahtjevom 2, naznačen time što sadrži 40-60% (tež./tež.) ugljikohidrata koji se mogu dobiti iz rogača, te 40-60% (tež./tež.) ugljikohidrata koji se mogu dobiti iz jabuke, gdje se postoci baziraju na suhoj tvari.
The composition of claim 4, comprising 35-45% (w/w) carbohydrates obtainable from carob, 40-50% (w/w) carbohydrates obtainable from apple, and 10-20% (w/w) carbohydrates obtainable from grape, wherein the percentages are based on the dry matter. 
Pripravak u skladu s patentnim zahtjevom 4, naznačen time što sadrži 35-45% (tež./tež.) ugljikohidrata koji se mogu dobiti iz rogača, 40-50% (tež./tež.) ugljikohidrata koji se mogu dobiti iz jabuke, te 10-20% (tež./tež.) ugljikohidrata koji se mogu dobiti iz grožđa, gdje se postoci baziraju na suhoj tvari.
The composition of any of claims 1 to 5, comprising carbohydrates obtainable from carob, apple, grape and pear. 
Pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što sadrži ugljikohidrate koji se mogu dobiti iz rogača, jabuke, grožđa i kruške.
The composition of claim 6, comprising 35-45% (w/w) carbohydrates obtainable from carob, 35-45% (w/w) carbohydrates obtainable from apple, 5-15 % (w/w) carbohydrates obtainable from grape, and 5-15% (w/w) carbohydrates obtainable from pear, wherein the percentages are based on the dry matter. 
Pripravak u skladu s patentnim zahtjevom 6, naznačen time što sadrži 35-45% (tež./tež.) ugljikohidrata koji se mogu dobiti iz rogača, 35-45% (tež./tež.) ugljikohidrata koje se mogu dobiti iz jabuke, 5-15 % (tež./tež.) ugljikohidrata koji se mogu dobiti iz grožđa, te 5-15% (tež./tež.) ugljikohidrata koji se mogu dobiti iz kruške, gdje se postoci baziraju na suhoj tvari.
The composition of any of claims 1 to 7, comprising carbohydrates obtainable from carob, apple, grape, pear, peach, orange and lemon. 
Pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što sadrži ugljikohidrate koji se mogu dobiti iz rogača, jabuke, grožđa, kruške, breskve, naranče i limuna.
obtaining a composition comprising carbohydrates from at least one further fruit, and 
dobivanje pripravka koji sadrži ugljikohidrate iz najmanje jednog dodatnog voća, i
and mixing the products of steps a) and b). 
miješanje rezultata iz koraka a) i b).
The process of any of claims 10 to 25, wherein the mixture in step c) is refined and decoloured by cation exchange chromatography, anion exchange chromatography, and/or adsorption chromatography. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 10 do 25, naznačen time što se smjesa u koraku c) rafinira i obezboji kationoizmjenjivačkom kromatografijom, anionoizmjenjivačkom kromatografijom i/ili adsorpcijskom kromatografijom.
Pharmaceutical composition comprising the composition of any of claims 1 to 12. Composition of any of claims 1 to 12 for the prevention or treatment of type 2 diabetes, cardiovascular disease, coronary heart disease, obesity or hyperlipidemia. 
Pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što je namijenjen upotrebi u sprječavanju ili liječenju dijabetesa tipa 2, kardiovaskularne bolesti, koronarne bolesti srca, pretilosti ili hiperlipidemije.